peptides for hip labral tear FAQ

Chronic labral tears (>12 months) that have already completed the remodeling phase are less likely to respond to peptide protocols. The window for modulating tissue healing is during the proliferative and early remodeling phases. Roughly weeks 2–16 post-injury. After 12 months, the tissue has formed stable (though potentially weak) scar tissue, and peptide administration won't reverse established fibrosis. Peptides may still reduce residual inflammation and improve pain tolerance, but structural tissue changes are unlikely at this stage.

If lyophilized peptides were exposed to temperatures above 25°C for more than 48 hours during shipping, degradation is likely but not certain. If reconstituted peptides were shipped without cold packs and reached ambient temperature, assume complete degradation. Peptides in solution denature irreversibly above 8°C. Contact the supplier for reshipment or refund. Do not inject a peptide that may have lost potency; you're injecting an expensive saline solution at best, and bacterial contamination risk increases with compromised storage.

Wait until the acute inflammatory phase resolves. Typically 10–14 days post-injury or post-surgery. Administering BPC-157 or TB-500 during peak inflammation (days 0–7) may increase joint effusion and pain by promoting excessive early angiogenesis before the injury zone is ready for tissue remodeling. The ideal start window is weeks 2–3, once inflammatory markers (CRP, IL-6) have begun declining and fibroblast proliferation is the dominant healing process.

Degenerative tears complicate peptide efficacy because they occur in tissue already damaged by chronic impingement or cartilage loss. BPC-157 can still stimulate angiogenesis, but if the underlying mechanical cause (femoral acetabular impingement, hip dysplasia) persists, the tear will recur. Address the biomechanical problem first. Either through surgical correction or activity modification. Then use peptides to support healing of the residual damage. Peptides are not a workaround for structural hip pathology; they're a biological adjunct to mechanical correction.

Non-response within 4–6 weeks suggests either inadequate dosing, poor peptide purity, or a tear severity that requires surgical intervention. Verify peptide source first. Compounded peptides from unverified suppliers may contain degraded or incorrectly sequenced product. Real Peptides provides third-party verified, small-batch synthesis with guaranteed amino-acid sequencing to eliminate this variable. If purity is confirmed and symptoms persist, imaging (MRI arthrogram) can assess whether the tear has progressed or whether additional pathology (cartilage damage, subchondral edema) is present. Peptides support healing; they don't override structural failure.

Combine them. Peptide protocols work best alongside structured rehabilitation. BPC-157 and TB-500 support tissue healing at the cellular level, but mechanical loading guides tissue remodeling. Physical therapy provides controlled stress that signals fibroblasts where to deposit collagen. Without mechanical stimulus, newly formed tissue lacks functional alignment. Standard approach: initiate peptides immediately after diagnosis, begin gentle range-of-motion exercises within 1–2 weeks, progress to resistance training at 6–8 weeks as pain allows. The peptides reduce inflammation and support vascularization; PT ensures the repaired tissue forms with functional architecture.